News | Pharmaceuticals | September 11, 2017

Merck Announces Results of REVEAL Outcomes Study of Anacetrapib

Investigational medicine for cardiovascular disease significantly reduced risk of major coronary events when combined with statin therapy

Merck Announces Results of REVEAL Outcomes Study of Anacetrapib

September 11, 2017 — Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and presentation of results from the REVEAL outcomes study of anacetrapib, Merck’s investigational cholesteryl ester transfer protein (CETP) inhibitor. In the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin, anacetrapib significantly reduced the risk of major coronary events (composite of coronary death, myocardial infarction or coronary revascularization) by 9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004). The safety of anacetrapib was generally consistent with data from earlier trials of the drug. However, a sub-study also showed that anacetrapib accumulates in adipose tissue with prolonged dosing.

Merck is reviewing the results of the trial with external experts and will consider whether to file new drug applications with the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

The results of REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) were presented by Martin Landray, MB, ChB, Ph.D., of the University of Oxford, the trial’s co-principal investigator, during a late-breaking clinical trials session at the European Society of Cardiology Congress, Aug. 26-30 in Barcelona, Spain, and simultaneously published in the online edition of The New England Journal of Medicine.

REVEAL was designed and independently conducted by investigators at the Clinical Trial Service Unit at the University of Oxford, the trial’s regulatory sponsor, in collaboration with the TIMI Study Group based at Brigham and Women’s Hospital in Boston and Merck. Merck provided funding for REVEAL.

In the randomized, double-blind, placebo-controlled clinical study, 30,449 adults with atherosclerotic vascular disease on study-mandated intensive atorvastatin therapy (mean baseline LDL cholesterol level 61 mg/dL [1.58 mmol/L], non-HDL cholesterol 92 mg/dL [2.38 mmol/L], and HDL cholesterol 40 mg/dL [1.03 mg/dL]) were randomly assigned to receive either anacetrapib 100 mg once daily or matching placebo. The primary assessment was an intention-to-treat comparison among all randomized participants of the effect of anacetrapib on the composite of major coronary events, defined as the first occurrence of coronary death, myocardial infarction or coronary revascularization.

Compared with placebo, the addition of anacetrapib further reduced the mean level of non-HDL cholesterol by 17 mg/dL (0.44 mmol/L,18%) and increased HDL cholesterol level by 43 mg/dL (1.12 mmol/L, 104%) at the study midpoint. During median follow-up of 4.1 years, a 9 percent relative reduction in the risk of major coronary events was observed among those receiving anacetrapib compared to placebo (1640 events [10.8%] versus 1,803 events [11.8%]; rate ratio 0.91; 95% CI 0.85 to 0.97; P=0.004). The benefit was similar across multiple pre-specified subgroups.

The difference in the key secondary composite outcome of major atherosclerotic events (myocardial infarction, coronary death or presumed ischemic stroke) did not reach statistical significance (rate ratio, 0.93; 95% CI, 0.86 to 1.00; P=0.052), possibly due to a lack of observed benefit of anacetrapib on presumed ischemic stroke. There were no statistically significant differences in cause-specific mortality, cancer or other serious adverse events. Anacetrapib produced small increases in systolic and diastolic blood pressures of 0.7 mmHg and 0.3 mmHg, respectively; there was no statistically significant increase of serious adverse events attributed to hypertension. Compared to those receiving placebo, more patients in the anacetrapib group developed an estimated glomerular filtration rate of less than 60 ml/min/1.73m2 by the end of the study (11.5% vs. 10.6%; P=0.04); there was no statistically significant impact on the development of albuminuria or serious adverse events attributed to renal failure.

For more information: www.escardio.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now